| Ytd | -26.51% | |
| 1y | -29.97% |
| Open | Prev Close | 4.02 | Low | High | Mkt Cap | 7.72M | |||
| Vol | 0.00 | Avg Vol | 28.41K | EPS | -16.33 | P/E | -0.25 | Forward P/E | -0.40 |
| Beta | 1.16 | Short Ratio | 0.54 | Inst. Own | 58.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 4.47 | 200-d Avg | 5.02 | 1yr Est | 1.75 |
BOLT News
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:B
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinic
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the recipient of a significant growt
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clin
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) ar
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the target of a large decrease in sh
Acumen Pharmaceuticals (NASDAQ: ABOS - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance o
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely
Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clini
Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Re
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks
During Thursday's session, 406 companies made new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.